NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
In support of the project in adopting Atlas Genetic's io rapid diagnostic platform into UK sexual health clinics, Innovative UK has awarded them a grant of £2 million.
Early asymptomatic nasopharyngeal carcinoma (NPC) will possibly be detectable by plasma Epstein-Barr virus (EBV) DNA analysis, according to a new study carried out by the Chinese University of Hong Kong (CUHK).
Transchiatal esophagectomy procedures utilizing robotic platforms are “effective and safe” for carefully selected patients, according to a new study from Allina Health hospitals.
A report examining the European venture landscape for health and biotech firms over the first half of 2017 has found that there is a continuing positive environment for venture funding and M&A in the sector.
RealView Imaging has integrated the Intel RealSense SR300-Series camera into its holographic augmented reality (AR) medical system, Holoscope-i.
The merger and acquisition information of CombiMatrix, Skyline Medical and Victory Square Technologies.
New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
US-based life sciences firm Emergent BioSolutions has secured around $23m for the development of a new multi-drug auto-injector to deliver nerve agent antidote.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.